脑心通胶囊联合替格瑞洛治疗冠心病心绞痛的临床研究  

Clinical study of Naoxintong capsule combined with ticagrelor in the treatment of angina pectoris of coronary heart disease

作　　者：吴婷婷[1] 李源 WU Ting-ting;LI Yuan(Department of Pharmacy,Jianhu County People's Hospital,Yancheng 224700,China)

机构地区：[1]建湖县人民医院药学部,224700 [2]建湖双湖中医院药剂科,224700

出　　处：《中国现代药物应用》2025年第6期17-20,共4页Chinese Journal of Modern Drug Application

摘　　要：目的评价冠心病心绞痛患者接受脑心通胶囊、替格瑞洛联合治疗的疗效。方法选择冠心病心绞痛患者86例,将患者采用抽签分组法分为研究组和对照组,每组43例。研究组接受脑心通胶囊、替格瑞洛联合治疗,对照组接受替格瑞洛治疗。对比两组疗效,不良反应发生情况,治疗前后心功能指标、心绞痛情况、心肌损伤指标及血清炎性因子水平。结果研究组总有效率为95.35%,高于对照组的79.07%(P<0.05)。两组不良反应发生率对比无差异(P>0.05)。研究组治疗后心搏量(SV)(58.46±9.60)ml、左心室射血分数(LVEF)(66.55±6.75)%高于对照组的(49.72±8.46)ml、(61.23±5.48)%(P<0.05)。研究组治疗后心绞痛持续时间(2.41±0.71)min/次、心绞痛发作频率(1.23±0.41)次/d、视觉模拟评分法(VAS)评分(2.30±0.72)分低于对照组的(3.12±0.84)min/次、(1.75±0.52)次/d、(3.27±0.94)分(P<0.05)。研究组治疗后肌红蛋白(MYO)(70.05±13.90)μg/L、肌酸激酶同工酶(CK-MB)(5.85±1.32)ng/ml、心肌肌钙蛋白I(cTnI)(0.05±0.01)ng/ml低于对照组的(85.02±15.03)μg/L、(7.28±1.82)ng/ml、(0.09±0.02)ng/ml(P<0.05)。研究组治疗后同型半胱氨酸(Hcy)(11.45±3.26)μmol/L、白细胞介素-6(IL-6)(114.33±20.25)pg/ml均低于对照组的(15.35±3.48)μmol/L、(132.38±20.16)pg/ml(P<0.05)。结论冠心病心绞痛患者接受脑心通胶囊、替格瑞洛联合治疗效果良好,有效性和安全性均较高,有利于心功能、心绞痛、心肌损伤、血清炎性因子改善,值得推广。Objective To evaluate the efficacy of Naoxintong capsule combined with ticagrelor in the treatment of patients with angina pectoris of coronary heart disease.Methods A total of 86 patients with angina pectoris of coronary heart disease were selected and divided into study group and control group by lottery method,with 43 cases in each group.The study group received Naoxintong capsule and ticagrelor combined treatment,and the control group received ticagrelor treatment.Comparison of efficacy,occurrence of adverse reactions,cardiac function indexes,angina pectoris,myocardial injury indexes and serum inflammatory factors before and after treatment between the two groups.Results The total effective rate of the study group was 95.35%,which was higher than 79.07%of the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the stroke volume(SV)in the study group was(58.46±9.60)ml and the left ventricular ejection fraction(LVEF)was(66.55±6.75)%,which were higher than(49.72±8.46)ml and(61.23±5.48)%in the control group(P<0.05).After treatment,the duration of angina pectoris in the study group was(2.41±0.71)min/time,the frequency of angina pectoris attack was(1.23±0.41)times/d,and the visual analogue scale(VAS)score was(2.30±0.72)points,which were lower than(3.12±0.84)min/time,(1.75±0.52)times/d,and(3.27±0.94)points in the control group(P<0.05).After treatment,the study group had myoglobin(MYO)of(70.05±13.90)μg/L,creatine kinase isoenzyme(CK-MB)of(5.85±1.32)ng/ml,and cardiac troponin I(cTnI)of(0.05±0.01)ng/ml,which were lower than(85.02±15.03)μg/L,(7.28±1.82)ng/ml,and(0.09±0.02)ng/ml in the control group(P<0.05).After treatment,the study group had homocysteine(Hcy)of(11.45±3.26)μmol/L and interleukin-6(IL-6)of(114.33±20.25)pg/ml,which were lower than(15.35±3.48)μmol/L and(132.38±20.16)pg/ml in the control group(P<0.05).Conclusion The combined treatment of Naoxintong capsule and ticagrelor in patients with angina pectoris of

关 键 词：冠心病心绞痛 替格瑞洛 脑心通胶囊 心肌损伤 

分 类 号：R541.4[医药卫生—心血管疾病]